Prime Medicine, Inc. Cash Flow Statement
PRME / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Prime Medicine, Inc. used $123M in operating cash flow and negative free cash flow of $130M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income | -$195.9M | -$198.1M | -$121.8M | -$165.4M | -$3.4M |
| Depreciation & Amortization | $6.1M | $4.7M | $2.2M | $568.0K | $43.0K |
| Operating Cash Flow | -$122.9M | -$165.4M | -$131.8M | -$34.1M | -$5.5M |
| Capital Expenditures | $7.3M | $8.7M | $16.1M | $4.2M | $639.0K |
| Free Cash Flow | -$130.2M | -$174.1M | -$147.9M | -$38.2M | -$6.2M |